2007

Novartis Defends Zelnorm Cardiovascular Safety Lawsuits

North America - United States

In 2007, the U.S. Food and Drug Administration requested that Novartis suspend marketing of its gastrointestinal drug Zelnorm amid possible questions with respect to cardiovascular safety data. Faegre Baker Daniels' drug and device product liability team served as national counsel to defend Novartis in the numerous products liability lawsuits brought following suspension, where plaintiffs claimed the drug caused heart attacks or strokes.

The Faegre Baker Daniels website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Baker Daniels' cookies information for more details.